par Halama, Niels;Zoernig, Inka;Berthel, Anna;Kahlert, Christoph;Klupp, Fee;Suarez-Carmona, Meggy
;Suetterlin, Thomas;Brand, Karsten;Krauss, Juergen;Lasitschka, Felix;Lerchl, Tina;Luckner-Minden, Claudia;Ulrich, Alexis;Koch, Moritz;Weitz, Juergen;Schneider, Martin;Buechler, Markus MW;Zitvogel, Laurence;Herrmann, Thomas T.R.;Benner, Axel;Kunz, Christina;Luecke, Stephan;Springfeld, Christoph;Grabe, Niels;Falk, Christine S;Jaeger, Dirk
Référence Cancer cell, 29, 4, page (587-601)
Publication Publié, 2016-04
;Suetterlin, Thomas;Brand, Karsten;Krauss, Juergen;Lasitschka, Felix;Lerchl, Tina;Luckner-Minden, Claudia;Ulrich, Alexis;Koch, Moritz;Weitz, Juergen;Schneider, Martin;Buechler, Markus MW;Zitvogel, Laurence;Herrmann, Thomas T.R.;Benner, Axel;Kunz, Christina;Luecke, Stephan;Springfeld, Christoph;Grabe, Niels;Falk, Christine S;Jaeger, DirkRéférence Cancer cell, 29, 4, page (587-601)
Publication Publié, 2016-04
Article révisé par les pairs
| Résumé : | The immune response influences the clinical course of colorectal cancer (CRC). Analyzing the invasive margin of human CRC liver metastases, we identified a mechanism of immune cell exploitation by tumor cells. While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5. CCR5 blockade in patient-derived functional in vitro organotypic culture models showed a macrophage repolarization with anti-tumoral effects. These anti-tumoral effects were then confirmed in a phase I trial with a CCR5 antagonist in patients with liver metastases of advanced refractory CRC. Mitigation of tumor-promoting inflammation within the tumor tissue and objective tumor responses in CRC were observed. |



